Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

24
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
24
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

26
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
26

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Standardized endpoint definitions for trials of transcatheter left atrial appendage closure: a consensus from the Left Atrial Appendage Academic Research Consortium†.

European heart journal·2026
Same author

Catheter Ablation of ARVC Ventricular Tachycardia With a Reverse R-Wave Pattern Break in Lead V2.

JACC. Clinical electrophysiology·2026
Same author

Prevalence and Clinical Impact of Pathogenic Variants in Cardiomyopathy Genes Among Individuals with Cardiac Conduction Disorders.

medRxiv : the preprint server for health sciences·2026
Same author

Feasibility and outcomes of repeat epicardial access in arrhythmogenic right ventricular cardiomyopathy.

Heart rhythm·2026
Same author

Catheter Ablation Versus Antiarrhythmic Drugs in the Management of Ventricular Tachycardia in Ischemic Cardiomyopathy: An Updated Systematic Review and Meta-analysis.

Cardiology in review·2026
Same author

Author's Reply to "Can artificial intelligence transform cardiomyopathy diagnosis and risk stratification in the Philippines?"

Heart rhythm O2·2026

相关实验视频

Updated: Sep 9, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

免疫抑制药物对皮肤穿透左耳附带塞住患者的影响

Daisuke Togashi1, Christopher R Ellis1, Zachary T Yoneda1

  • 1Cardiovascular Division, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Journal of cardiovascular electrophysiology
|August 29, 2025
PubMed
概括

在接受免疫抑制疗法 (IMS) 的患者中,穿皮左心房附带关闭 (LAAC) 是安全的. 虽然术后结果相似,但这些患者在随访期间面临更高的全身感染率和较低的器械外泄改善.

关键词:
与装置相关的血栓免疫抑制药物左心房附属体的关闭非膜心房动周围设备的泄漏

更多相关视频

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K

相关实验视频

Last Updated: Sep 9, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K

科学领域:

  • 心脏病学
  • 干预心脏病学
  • 医疗器械

背景情况:

  • 在无法使用口服抗凝药的非膜性心房动患者中,穿皮左心房关闭 (LAAC) 是一种降低中风风险的策略.
  • 在慢性免疫抑制治疗 (IMS) 的患者中,LAAC的结果尚未确立.

研究的目的:

  • 评估长期接受IMS治疗的患者皮肤穿透的LAAC的安全性和有效性.
  • 为了比较IMS和非IMS患者的术后和长期结果.

主要方法:

  • 在2017年11月至2023年3月接受LAAC的1172名患者的回顾性评估.
  • 根据长期免疫抑制疗法 (IMS) 的使用情况对患者进行分类.
  • 分析包括外科手术后的并发症,临床结果和设备后续特征,包括外科设备泄漏 (PDL) 和设备相关的血栓.

主要成果:

  • 在IMS和非IMS组之间,手术后并发症没有显著差异 (1.4%对1.3%).
  • 在平均617天的随访期间,IMS组的系统性感染发病率较高 (25. 0%对6. 1%).
  • 在周围设备泄漏 (PDL) 或与设备相关的血栓没有显著差异,但在IMS组中PDL的改善较低 (8. 3%与50. 0%相比).

结论:

  • 通过皮肤的LAAC可以在慢性IMS患者中成功进行,而不会增加外科手术后的风险.
  • 长期随访显示,在LAAC治疗后,IMS患者的全身感染风险增加.
  • 随着时间的推移,IMS使用与周围设备泄漏的改善有关.